Emerging families of biomarkers for coronary artery disease: Inflammatory mediators

Vascular Health and Risk Management

Volumn 9, Issue 1, 2013, Pages 435-456

  Yayan, Josef ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Arteriosclerosis; Biomarkers; Coronary artery disease; Inflammation; Markers; Myocardial infarction

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ACETYLSALICYLIC ACID; ACUTE PHASE PROTEIN; AMYLOID A PROTEIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD40 LIGAND; CLOPIDOGREL; FIBRINOGEN; GALECTIN 3; HOMOCYSTEINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 27; INTERLEUKIN 33; INTERLEUKIN 6; LYSOPHOSPHATIDYLCHOLINE; MYELOID RELATED PROTEIN 14; MYELOID RELATED PROTEIN 8; MYELOPEROXIDASE; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PENTRAXIN 3; PREGNANCY ASSOCIATED PLASMA PROTEIN A; PROTEIN ST2; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TROPONIN T; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ALBUMIN TO CREATININE RATIO; BASOPHIL; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR PARAMETERS; CORONARY ARTERY DISEASE; CORONARY RISK; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; EARLY DIAGNOSIS; ENDOTHELIAL PROGENITOR CELL; EOSINOPHIL COUNT; ERYTHROCYTE SEDIMENTATION RATE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; LIPID METABOLISM; MONOCYTE; NEUTROPHIL COUNT; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

ARTERIOSCLEROSIS; BIOMARKERS; CORONARY ARTERY DISEASE; INFLAMMATION; MARKERS; MYOCARDIAL INFARCTION;

BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; HUMANS; INFLAMMATION MEDIATORS; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 84889770848     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S45704     Document Type: Review

References (113)

1. Morrow DA, Sabatine MS, Brennan ML, et al. Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J. 2008;29(9):1096-1102.
2. Nagesh CM, Roy A. Role of biomarkers in risk stratification of acute coronary syndrome. Indian J Med Res. 2010;132:627-633.
3. Kumar A, Cannon CP. Acute coronary syndromes: diagnosis and management, part I. Mayo Clin Proc. 2009;84(10):917-938.
4. James SK, Armstrong P, Barnathan E, et al; GUSTO-IV-ACS Investigators. Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. J Am Coll Cardiol. 2003;41(6):916-924.
5. Morrow DA, de Lemos JA, Sabatine MS, Antman EM. The search for a biomarker of cardiac ischemia. Clin Chem. 2003;49(4):537-539.
6. Pearson TA, Mensah GA, Alexander, RA, et al; Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107(3):499-511.
7. Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation. 2006;113(19):2335-2362.
8. Apple FS, Wu AH, Mair J, et al; Committee on Standardization of Markers of Cardiac Damage of the IFCC. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem. 2005;51(5):810-824.
9. Morrow DA, Braunwald E. Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy. Circulation. 2003;108(3):250-252.
10. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992;326(4):242-250.
11. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340(2):115-126.
12. Harris TB, Ferrucci L, Tracy RP, et al. Association of elevated interleukin-6 and C-reactive protein levels with mortality in elderly. Am J Med. 1999;106(5):506-512.
13. Beck BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol. 1990;65(3): 168-172.
14. de Beer FC, Hind CR, Fox KM, Allan RM, Maseri A, Pepys MB. Measurement of serum C-reactive protein concentration in myocardial ischemia and infarction. Br Heart J. 1982;47(3):239-243.
15. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med. 1994;331(7):417-424.
16. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342(12):836-843.
17. Ridker PM, Rifai N, Clearfield M, et al; Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344(26): 1959-1965.
18. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998;97(20):2007-2011.
19. Chew DP, Bhatt DL, Robbins MA, et al. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation. 2001;104(9): 992-997.
20. Heeschen C, Hamm CW, Bruemmer J, Simoons ML. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 Antiplatelet Therapy in Unstable angina Refractory to standard treatment trial. J Am Coll Cardiol. 2000;35(6):1535-1542.
21. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med. 2000;343(16):1139-1147.
22. Biasucci LM, Liuzzo G, Grillo RL, et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation. 1999;99(7):855-860.
23. de Winter RJ, Bholasingh R, Lijmer JG, et al. Independent prognostic value of C-reactive protein and troponin I in patients with unstable angina or non-Q-wave myocardial infarction. Cardiovasc Res. 1999;42(1):240-245.
24. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary artery disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol. 1996;144(6):537-547.
25. Noh HJ, Kwon NH, Joo SB. Severity of coronary atherosclerosis; influence of metabolic syndrome risk factor clustering and hs-CRP. Korean Circ J. 2006;36(12):802-808.
26. Doo YC, Park WJ, Park SH, et al. The optimal timing to measure C-reactive protein to predict cardiac events in patients with unstable angina. Korean Circ J. 2001;31(3):290-296.
27. Kim TI, Chae SC, Yang DH, et al. Short-term prognostic value of CRP in the patients with acute coronary syndrome. Korean Circ J. 2000;30(11): 1387-1394.
28. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet. 1997;349(9050):462-466.
29. Rossi E, Biasucci LM, Citterio F, et al. Risk of myocardial infarction and angina in patients with severe peripheral vascular disease: predictive role of C-reactive protein. Circulation. 2002;105(7):800-803.
30. Rolph MS, Zimmer S, Bottazzi B, Garlanda C, Mantovani A, Hansson GK. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2002;22(5):e10-e14.
31. Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol. 2005;23:337-366.
32. Peri G, Introna M, Corradi D, et al. PTX3, a prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation. 2000;102(6):636-641.
33. Latini R, Maggioni AP, Peri G, et al; Lipid Assessment Trial Italian Network (LATIN) Investigators. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation. 2004;110(16):2349-2354.
34. Dubin R, Li Y, Ix JH, Shlipak MG, Whooley M, Peralta CA. Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary artery disease: data from the Heart and Soul Study. Am Heart J. 2012;163(2): 274-279.
35. Jenny NS, Arnold AM, Kuller LH, Tracy RP, Psaty BM. Associations of pentraxin 3 with cardiovascular disease and all-cause death: the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 2009;29(5): 594-599.
36. Lee DH, Jeon HK, You JH, et al. Pentraxin 3 as a novel marker predicting congestive heart failure in subjects with acute coronary syndrome. Korean Circ J. 2010;40(8):370-376.
37. Alam N, Khan HI, Chowdhury AW, et al. Elevated serum homocysteine level has a positive correlation with serum cardiac troponin I in patients with acute myocardial infarction. Bangladesh Med Res Counc Bull. 2012;38(1):9-13.
38. Washio T, Nomoto K, Watanabe I, Tani S, Nagao K, Hirayama A. Relationship between plasma homocysteine levels and congestive heart failure in patients with acute myocardial infarction. Homocysteine and congestive heart failure. Int Heart J. 2011;52(4):224-228.
39. Agoşton-Coldea L, Mocan T, Seicean A, Gatfossé M, Rosenstingl S. The plasma homocysteine concentrations and prior myocardial infarction. Rom J Intern Med. 2010;48(1):65-72.
40. Kosuge M, Ebina T, Ishikawa T, et al. Serum amyloid A is a better predictor of clinical outcomes than C-reactive protein in non-ST-segment elevation acute coronary syndromes. Circ J. 2007;71(2):186-190.
41. Katayama T, Nakashima H, Takagi C, et al. Prognostic value of serum amyloid A protein in patients with acute myocardial infarction. Circ J. 2005;69(10):1186-1191.
42. Johnson BD, Kip KE, Marroquin OC, et al; National Heart, Lung, and Blood Institute. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation. 2004;109(6):726-732.
43. Tousoulis D, Papageorgiou N, Androulakis E, Briasoulis A, Antoniades C, Stefanadis C. Fibrinogen and cardiovascular disease: genetics and biomarkers. Blood Rev. 2011;25(6):239-245.
44. Reinhart WH. Fibrinogen-marker or mediator of vascular disease? Vasc Med. 2003;8(3):211-216.
45. Coppola G, Rizzo M, Abrignani MG, et al. Fibrinogen as a predictor of mortality after acute myocardial infarction: a forty-two-month follow-up study. Ital Heart J. 2005;6(4):315-322.
46. Yayan J. Erythrocyte sedimentation rate as a marker for coronary heart disease. Vasc Health Risk Manag. 2012;8:219-223.
47. Erikssen G, Liestøl K, Bjørnholt JV, Stormorken H, Thaulow E, Erikssen J. Erythrocyte sedimentation rate: a possible marker of atherosclerosis and a strong predictor of coronary heart disease mortality. Eur Heart J. 2000;21(19):1614-1620.
48. Timmer JR, Ottervanger JP, Hoorntje JC, et al; Zwolle Myocardial Infarction study group. Prognostic value of erythrocyte sedimentation rate in ST segment elevation myocardial infarction: interaction with hyperglycaemia. J Intern Med. 2005;257(5):423-429.
49. van der Laan AM, Hirsch A, Robbers LF, et al. A proinflammatory monocyte response is associated with myocardial injury and impaired functional outcome in patients with ST-segment elevation myocardial infarction: monocytes and myocardial infarction. Am Heart J. 2012;163(1):57-65. e2.
50. Tousoulis D, Androulakis E, Papageorgiou N, et al. From atherosclerosis to acute coronary syndromes: the role of soluble CD40 ligand. Trends Cardiovasc Med. 2010;20(5):153-164.
51. Setianto BY, Hartopo AB, Achadiono DN, Gharini PP. Association between levels of circulating soluble CD40 ligand on admission and in-hospital events among acute coronary syndrome patients. Acta Med Indones. 2011;43(2):82-87.
52. Jefferis BJ, Whincup PH, Welsh P, et al. Prospective study of circulating soluble CD40 ligand concentrations and the incidence of cardiovascular disease in a nested prospective case-control study of older men and women. J Thromb Haemost. 2011;9(8):1452-1459.
53. Abramson N, Melton B. Leukocytosis: basics of clinical assessment. Am Fam Physician. 2000;62(9):2053-2060.
54. Grau AJ, Boddy AW, Dukovic DA, et al; CAPRIE Investigators. Leukocyte count as an independent predictor of recurrent ischemic events. Stroke. 2004;35(5):1147-1152.
55. Akhtar N, Adil MM, Ahmed W, Habib-ur-Rehman, Shahs MA. The role of leukocyte counts in patients with unstable angina pectoris or myocardial infarction; prognostic significance and correlation with plasma brain natriuretic peptide (BNP) levels. J Pak Med Assoc. 2011;61(1):51-54.
56. Björkbacka H, Lavant EH, Fredrikson GN, et al. Weak associations between human leucocyte antigen genotype and acute myocardial infarction. J Intern Med. 2010;268(1):50-58.
57. Meissner J, Irfan A, Twerenbold R, et al. Use of neutrophil count in early diagnosis and risk stratification of AMI. Am J Med. 2011;124(6): 534-542.
58. Maugeri N, Rovere-Querini P, Evangelista V, et al. An intense and short-lasting burst of neutrophil activation differentiates early acute myocardial infarction from systemic inflammatory syndromes. PLoS ONE. 2012;7(6):e39484.
59. Murasaki S, Murasaki K, Tanoue K, Kawana M, Hagiwara N, Kasanuki H. Circulating platelet and neutrophil activation correlates with the clinical course of unstable angina. Heart Vessels. 2007;22(6): 376-382.
60. Schaub N, Reichlin T, Meune C, et al. Markers of plaque instability in the early diagnosis and risk stratification of acute myocardial infarction. Clin Chem. 2012;58(1):246-256.
61. Baldus S, Heeschen C, Meinertz T, et al; CAPTURE Investigators. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation. 2003;108(12):1440-1445.
62. Brennan ML, Penn MS, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003;349(17):1595-1604.
63. Stankovic S, Asanin M, Majkic-Singh N, et al. The usefulness of myeloperoxidase in prediction of in-hospital mortality in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention. Clin Lab. 2012;58(1-2):125-131.
64. Morrow DA, Wang Y, Croce K, et al. Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial. Am Heart J. 2008;155(1):49-55.
65. Bonaca MP, Scirica BM, Sabatine MS, et al. Prospective evaluation of pregnancy-associated plasma protein-a and outcomes in patients with acute coronary syndromes. J Am Coll Cardiol. 2012;60(4):332-338.
66. Iversen KK, Dalsgaard M, Teisner AS, et al. Pregnancy-associated plasma protein-A, a marker for outcome in patients suspected for acute coronary syndrome. Clin Biochem. 2010;43(10-11):851-857.
67. Khan DA, Sharif MS, Khan FA. Diagnostic performance of high-sensitivity troponin T, myeloperoxidase, and pregnancy-associated plasma protein A assays for triage of patients with acute myocardial infarction. Korean J Lab Med. 2011;31(3):172-178.
68. Kobayashi N, Hata N, Kume N, et al. Soluble lectin-like oxidized low-density lipoprotein receptor-1 as an early biomarker for ST elevation myocardial infarction: time-dependent comparison with other biomarkers: time-dependent comparison with other biomarkers. Circ J. 2011;75(6):1433-1439.
69. Hayashida K, Kume N, Murase T, et al. Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels are elevated in acute coronary syndrome: a novel marker for early diagnosis. Circulation. 2005;112(6):812-818.
70. Dohi T, Miyauchi K, Okazaki S, et al. Decreased circulating lipoprotein-associated phospholipase A2 levels are associated with coronary plaque regression in patients with acute coronary syndrome. Atherosclerosis. 2011;219(2):907-912.
71. Garg PK, McClelland RL, Jenny NS, et al. Association of lipoprotein-associated phospholipase A(2) and endothelial function in the Multi-Ethnic Study of Atherosclerosis (MESA). Vasc Med. 2011;16(4): 247-252.
72. Heart Protection Study Collaborative Group. Lipoprotein-associated phospholipase A2 activity and mass in relation to vascular disease and nonvascular mortality. J Intern Med. 2010;268(4):348-358.
73. Mallat Z, Lambeau G, Tedgui A. Lipoprotein-associated and secreted phospholipases A2 in cardiovascular disease: roles as biological effectors and biomarkers. Circulation. 2010;122(21):2183-2200.
74. Gonçalves I, Edsfeldt A, Ko NY, et al. Evidence supporting a key role of Lp-PLA2-generated lysophosphatidylcholine in human atherosclerotic plaque inflammation. Arterioscler Thromb Vasc Biol. 2012;32(6):1505-1512.
75. Falcone C, Lucibello S, Mazzucchelli I, et al. Galectin-3 plasma levels and coronary artery disease: a new possible biomarker of acute coronary syndrome. Int J Immunopathol Pharmacol. 2011;24(4):905-913.
76. López-Mejías R, García-Bermúdez M, González-Juanatey C, et al. Lack of association of IL6R rs2228145 and IL6ST/gp130 rs2228044 gene polymorphisms with cardiovascular disease in patients with rheumatoid arthritis. Tissue Antigens. 2011;78(6):438-441.
77. van Diepen S, Roe MT, Lopes RD, et al. Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trial. J Thromb Thrombolysis. 2012;34(1):106-113.
78. Fan ZX, Hua Q, Li YP, Liu RK, Yang Z. Interleukin-6, but not soluble adhesion molecules, predicts a subsequent mortality from cardiovascular disease in patients with acute ST-segment elevation myocardial infarction. Cell Biochem Biophys. 2011;61(2):443-448.
79. Cavusoglu E, Marmur JD, Hojjati MR, et al. Plasma interleukin-10 levels and adverse outcomes in acute coronary syndrome. Am J Med. 2011;124(8):724-730.
80. Welsh P, Murray HM, Ford I, et al; PROSPER Study Group. Circulating interleukin-10 and risk of cardiovascular events: a prospective study in the elderly at risk. Arterioscler Thromb Vasc Biol. 2011;31(10): 2338-2344.
81. Jafarzadeh A, Esmaeeli-Nadimi A, Nough H, Nemati M, Rezayati MT. Serum levels of interleukin (IL)-13, IL-17 and IL-18 in patients with ischemic heart disease. Anadolu Kardiyol Derg. 2009;9(2): 75-83.
82. Jafarzadeh A, Nemati M, Rezayati MT. Serum levels of interleukin (IL)-27 in patients with ischemic heart disease. Cytokine. 2011;56(2): 153-156.
83. Dhillon OS, Narayan HK, Quinn PA, Squire IB, Davies JE, Ng LL. Interleukin 33 and ST2 in non-ST-elevation myocardial infarction: comparison with Global Registry of Acute Coronary Events Risk Scoring and NT-proBNP. Am Heart J. 2011;161(6):1163-1170.
84. Kunes P, Holubcova Z, Kolackova M, Krejsek J. Interleukin-33, a novel member of the IL-1/IL-18 cytokine family, in cardiology and cardiac surgery. Thorac Cardiovasc Surg. 2010;58(8):443-449.
85. Suchanek H, Myśliwska J, Siebert J, et al. High serum interleukin-18 concentrations in patients with coronary artery disease and type 2 diabetes mellitus. Eur Cytokine Netw. 2005;16(3):177-185.
86. Patti G, Mega S, Pasceri V, et al. Interleukin-1 receptor antagonist levels correlate with extent of myocardial loss in patients with acute myocardial infarction. Clin Cardiol. 2005;28(4):193-196.
87. Devaux Y, Bousquenaud M, Rodius S, et al. Transforming growth factor β receptor 1 is a new candidate prognostic biomarker after acute myocardial infarction. BMC Med Genomics. 2011;4:83.
88. Oemrawsingh RM, Lenderink T, Akkerhuis KM, et al; CAPTURE investigators. Multimarker risk model containing troponin-T, interleukin 10, myeloperoxidase and placental growth factor predicts long-term cardiovascular risk after non-ST-segment elevation acute coronary syndrome. Heart. 2011;97(13):1061-1066.
89. Dizdarević-Hudić L, Kusljugić Z, Baraković F, et al. Correlation between interleukin 6 and interleukin 10 in acute myocardial infarction. Bosn J Basic Med Sci. 2009;9(4):301-306.
90. Mälarstig A, Eriksson P, Hamsten A, Lindahl B, Wallentin L, Siegbahn A. Raised interleukin-10 is an indicator of poor outcome and enhanced systemic inflammation in patients with acute coronary syndrome. Heart. 2008;94(6):724-729.
91. Paakkanen R, Lokki ML, Seppänen M, Tierala I, Nieminen MS, Sinisalo J. Proinflammatory HLA-DRB1*01-haplotype predisposes to ST-elevation myocardial infarction. Atherosclerosis. 2012;221(2): 461-466.
92. Chang LT, Yuen CM, Sun CK, et al. Role of stromal cell-derived factor-1alpha, level and value of circulating interleukin-10 and endothelial progenitor cells in patients with acute myocardial infarction undergoing primary coronary angioplasty. Circ J. 2009;73(6): 1097-1104.
93. Eitel I, Blase P, Adams V, et al. Growth-differentiation factor 15 as predictor of mortality in acute reperfused ST-elevation myocardial infarction: insights from cardiovascular magnetic resonance. Heart. 2011;97(8):632-640.
94. Schaub N, Reichlin T, Twerenbold R, et al. Growth differentiation factor-15 in the early diagnosis and risk stratification of patients with acute chest pain. Clin Chem. 2012;58(2):441-449.
95. Harutyunyan MJ, Mathiasen AB, Winkel P, et al; CLARICOR Trial Group. High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR trial. Scand J Clin Lab Invest. 2011;71(1):52-62.
96. Pemberton CJ, Siriwardena M, Kleffmann T, et al. First identification of circulating prepro-A-type natriuretic peptide (preproANP) signal peptide fragments in humans: initial assessment as cardiovascular biomarkers. Clin Chem. 2012;58(4):757-767.
97. Berton G, Cordiano R, Palmieri R, Cavuto F, Buttazzi P, Palatini P. Comparison of C-reactive protein and albumin excretion as prognostic markers for 10-year mortality after myocardial infarction. Clin Cardiol. 2010;33(8):508-515.
98. Kim JS, Hwang HJ, Ko YG, et al. Ischemia-modified albumin: is it a reliable diagnostic and prognostic marker for myocardial ischemia in real clinical practice? Cardiology. 2010;116(2):123-129.
99. Wudkowska A, Goch J, Goch A. Ischemia-modified albumin in differential diagnosis of acute coronary syndrome without ST elevation and unstable angina pectoris. Kardiol Pol. 2010;68(4):431-437.
100. Kavsak PA, Hill SA, Bhanich Supapol W, Devereaux PJ, Worster A. Biomarkers for predicting serious cardiac outcomes at 72 hours in patients presenting early after chest pain onset with symptoms of acute coronary syndromes. Clin Chem. 2012;58(1):298-302.
101. Haas B, Serchi T, Wagner DR, et al. Proteomic analysis of plasma samples from patients with acute myocardial infarction identifies haptoglobin as a potential prognostic biomarker. J Proteomics. 2011;75(1):229-236.
102. Charpentier S, Ducassé JL, Cournot M, et al. Clinical assessment of ischemia-modified albumin and heart fatty acid-binding protein in the early diagnosis of non-ST-elevation acute coronary syndrome in the emergency department. Acad Emerg Med. 2010;17(1):27-35.
103. Bali L, Cuisset T, Giorgi R, et al. Prognostic value of ischaemia-modified albumin in patients with non-ST-segment elevation acute coronary syndromes. Arch Cardiovasc Dis. 2008;101(10): 645-651.
104. Holm J, Ravn J, Ingemann Hansen S. Urinary excretion of alpha1-microglobulin and albumin in acute myocardial infarction. Correlation with plasma concentrations of troponin I and C-reactive protein. Scand J Urol Nephrol. 2006;40(4):339-344.
105. Ataoǧlu HE, Yilmaz F, Uzunhasan I, et al. Procalcitonin: a novel cardiac marker with prognostic value in acute coronary syndrome. J Int Med Res. 2010;38(1):52-61.
106. Bektas F, Soyuncu S, Gunduz I, Basarici I, Akbas H, Eken C. The value of procalcitonin, a novel inflammatory marker, in the diagnosis of myocardial infarction and evaluation of acute coronary syndrome patients. J Emerg Med. 2011;41(5):524-530.
107. Kelly D, Khan SQ, Dhillon O, et al. Procalcitonin as a prognostic marker in patients with acute myocardial infarction. Biomarkers. 2010;15(4):325-331.
108. Kafkas N, Venetsanou K, Patsilinakos S, et al. Procalcitonin in acute myocardial infarction. Acute Card Care. 2008;10(1):30-36.
109. Schiopu A, Hedblad B, Engström G, Struck J, Morgenthaler NG, Melander O. Plasma procalcitonin and the risk of cardiovascular events and death: a prospective population-based study. J Intern Med. 2012;272(5):484-491.
110. Tan K, Lu S, Chen Y, et al. CXC chemokine ligand 16 as a prognostic marker in patients with intermediate coronary artery lesions: a 2-year follow-up study. Tohoku J Exp Med. 2011;223(4):277-283.
111. Ng LL, Khan SQ, Narayan H, Quinn P, Squire IB, Davies JE. Proteinase 3 and prognosis of patients with acute myocardial infarction. Clin Sci. 2011;120(6):231-238.
112. Palikhe A, Sinisalo J, Seppänen M, et al. Serum complement C3/C4 ratio, a novel marker for recurrent cardiovascular events. Am J Cardiol. 2007;99(7):890-895.
113. Witkowska AM. Soluble ICAM-1: a marker of vascular inflammation and lifestyle. Cytokine. 2005;31(2):127-134.